Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | Outperform → Mkt Perform | Raymond James | |
| 6/18/2024 | $12.00 | Outperform | Raymond James |
| 5/25/2023 | $18.00 → $15.00 | Buy | Jefferies |
| 12/8/2022 | $11.00 | Buy | H.C. Wainwright |
| 9/23/2022 | $12.00 | Buy | Chardan Capital Markets |
| 8/24/2021 | $36.00 | Outperform | Wedbush |
| 8/24/2021 | $30.00 | Buy | Jefferies |
| 8/24/2021 | $30.00 | Overweight | Piper Sandler |
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)
Ratings for Omega Therapeutics (NASDAQ:OMGA) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $9.83, with a high estimate of $12.00 and a low estimate of $7.00. This current average has decreased by 4.1% f
Raymond James analyst Ryan Deschner initiates coverage on Omega Therapeutics (NASDAQ:OMGA) with a Outperform rating and announces Price Target of $12.
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev
Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev
8-K - Omega Therapeutics, Inc. (0001850838) (Filer)
10-Q - Omega Therapeutics, Inc. (0001850838) (Filer)
8-K - Omega Therapeutics, Inc. (0001850838) (Filer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
4 - Omega Therapeutics, Inc. (0001850838) (Issuer)
3 - Omega Therapeutics, Inc. (0001850838) (Issuer)
All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC, a historically ‘undruggable' target First-known clinical observation of pre-transcriptional gene modulation using a programmable epigenomic mRNA candidate Clinical proof-of-platform established; potential applicability across a broad range of diseases Company to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmabl
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET. The webcast will feature members of Omega's leadership team as well as a moderated discussion with Gerard Evan, Ph.D., Principal Group Leader of the Francis Crick Institute in London and Professor of Cancer Biology, King's College London. The live we
Raymond James downgraded Omega Therapeutics from Outperform to Mkt Perform
Raymond James initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $12.00
Jefferies resumed coverage of Omega Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously